European Breast Cancer Conference manifesto on breast centres/units

Lithium exposure and risk of dementia and Alzheimer's disease: A systematic review and meta-analysis.

Journal of Alzheimer's disease : JAD·2026

70-gene signature MammaPrint for early-stage HR-positive, HER2-negative breast cancer: Outcome in the MINDACT trial for key clinical-pathological high-risk subgroups.

European journal of cancer (Oxford, England : 1990)·2026

Pembrolizumab plus chemotherapy followed by pembrolizumab in participants in Asia with early triple-negative breast cancer: An updated subgroup analysis of the KEYNOTE-522 randomized clinical trial.

Breast (Edinburgh, Scotland)·2026

Which quality of life issues are important to patients with metastatic breast cancer: Phase 1 and 2 development of European Organisation for Research and Treatment of Cancer metastatic breast cancer module (EORTC QLQ-MBR).

Breast (Edinburgh, Scotland)·2026

Use of risperidone in-situ microparticles in real world: patterns of prescription and dose selection in patients with psychotic disorders.

International clinical psychopharmacology·2026

Mediterranean diet impact on plasma proteins: biomarker networks linking nutrition to the modulation of inflammation and oxidative stress.

Frontiers in nutrition·2026

Tumour-first DNA testing as a gateway to germline screening in patients with metastatic prostate cancer.

European journal of cancer (Oxford, England : 1990)·2026

Prophylactic use of G-CSFs to reduce neutropenia rates in patients treated with antibody-drug conjugates: A literature review.

European journal of cancer (Oxford, England : 1990)·2026

Safety and tolerability of anselamimab in participants with light chain amyloidosis: Results from a phase 2 study.

European journal of cancer (Oxford, England : 1990)·2026

Direct Tumor-Adipocyte Contact as a Prognostic Biomarker in Resected Pancreatic Ductal Adenocarcinoma.

European journal of cancer (Oxford, England : 1990)·2026

Biomarker-defined benefit from FLOT plus nivolumab in metastatic gastroesophageal cancer: Extended follow-up and immune-inflammatory markers of the phase II IKF-AIO-moonlight trial.

European journal of cancer (Oxford, England : 1990)·2026

Steroidogenesis inhibitor ODM-209 for metastatic castration-resistant prostate cancer and advanced breast cancer: Results from the first-in-human STESIDES study.

European journal of cancer (Oxford, England : 1990)·2026

A Markov model cost threshold analysis of potential hepatitis B virus cure regimens.

Clinical and translational gastroenterology·2026

Efficacy and safety of radiofrequency hyperthermia combined with immune checkpoint inhibitors and chemotherapy as first-line treatment for HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma: A propensity score-matched study.

Human vaccines & immunotherapeutics·2026

Pembrolizumab and Peptide Receptor Radionuclide Therapy for Patients with Metastatic Well-Differentiated Neuroendocrine Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Clinical outcomes and blood-based biomarkers across two SABR-treated metastatic settings: oligoprogression under immune checkpoint inhibition and oligometastatic disease.

Oncoimmunology·2026

Is there a role for palliative care in CAR T-cell therapy?

Current opinion in supportive and palliative care·2026

Synergistic Antitumor Effects and Reduced Systemic Toxicity of Berberine Chloride Combined With Cisplatin in a Female BALB/c Mouse Xenograft Model.

Cell biology international·2026

Related Experiment Videos

European Breast Cancer Conference manifesto on breast centres/units

Related Concept Videos

Lithium exposure and risk of dementia and Alzheimer's disease: A systematic review and meta-analysis.

70-gene signature MammaPrint for early-stage HR-positive, HER2-negative breast cancer: Outcome in the MINDACT trial for key clinical-pathological high-risk subgroups.

Pembrolizumab plus chemotherapy followed by pembrolizumab in participants in Asia with early triple-negative breast cancer: An updated subgroup analysis of the KEYNOTE-522 randomized clinical trial.

Which quality of life issues are important to patients with metastatic breast cancer: Phase 1 and 2 development of European Organisation for Research and Treatment of Cancer metastatic breast cancer module (EORTC QLQ-MBR).

Use of risperidone in-situ microparticles in real world: patterns of prescription and dose selection in patients with psychotic disorders.

Mediterranean diet impact on plasma proteins: biomarker networks linking nutrition to the modulation of inflammation and oxidative stress.

Tumour-first DNA testing as a gateway to germline screening in patients with metastatic prostate cancer.

Prophylactic use of G-CSFs to reduce neutropenia rates in patients treated with antibody-drug conjugates: A literature review.

Safety and tolerability of anselamimab in participants with light chain amyloidosis: Results from a phase 2 study.

Direct Tumor-Adipocyte Contact as a Prognostic Biomarker in Resected Pancreatic Ductal Adenocarcinoma.

Biomarker-defined benefit from FLOT plus nivolumab in metastatic gastroesophageal cancer: Extended follow-up and immune-inflammatory markers of the phase II IKF-AIO-moonlight trial.

Steroidogenesis inhibitor ODM-209 for metastatic castration-resistant prostate cancer and advanced breast cancer: Results from the first-in-human STESIDES study.

A Markov model cost threshold analysis of potential hepatitis B virus cure regimens.

Efficacy and safety of radiofrequency hyperthermia combined with immune checkpoint inhibitors and chemotherapy as first-line treatment for HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma: A propensity score-matched study.

Pembrolizumab and Peptide Receptor Radionuclide Therapy for Patients with Metastatic Well-Differentiated Neuroendocrine Tumors.

Clinical outcomes and blood-based biomarkers across two SABR-treated metastatic settings: oligoprogression under immune checkpoint inhibition and oligometastatic disease.

Is there a role for palliative care in CAR T-cell therapy?

Synergistic Antitumor Effects and Reduced Systemic Toxicity of Berberine Chloride Combined With Cisplatin in a Female BALB/c Mouse Xenograft Model.

Related Experiment Videos

European Breast Cancer Conference manifesto on breast centres/units

Abstract:

Related Concept Videos

Related Articles